Myopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative review

dc.contributor.authorMoreno, Carlos A Ibarra
dc.contributor.authorSilva, Helga Cristina Almeida da [UNIFESP]
dc.contributor.authorVoermans, Nicol C
dc.contributor.authorJungbluth, Heinz
dc.contributor.authorBersselaar, Luuk R. van den
dc.contributor.authorRendu, John
dc.contributor.authorCieniewicz , Agnieszka
dc.contributor.authorHopkins, Philip M
dc.contributor.authorRiazi, Sheila
dc.contributor.authorLatteshttp://lattes.cnpq.br/0844918862241102
dc.date.accessioned2024-08-07T15:03:55Z
dc.date.available2024-08-07T15:03:55Z
dc.date.issued2024-08-05
dc.description.abstractMalignant hyperthermia susceptibility (MHS) designates individuals at risk of developing a hypermetabolic reaction triggered by halogenated anaesthetics or the depolarising neuromuscular blocking agent suxamethonium. Over the past few decades, beyond the operating theatre, myopathic manifestations impacting daily life are increasingly recognised as a prevalent phenomenon in MHS patients. At the request of the European Malignant Hyperthermia Group, we reviewed the literature and gathered the opinion of experts to define MHS-related myopathy as a distinct phenotype expressed across the adult lifespan of MHS patients unrelated to anaesthetic exposure; this serves to raise awareness about non-anaesthetic manifestations, potential therapies, and management of MHS-related myopathy. We focused on the clinical presentation, biochemical and histopathological findings, and the impact on patient well-being. The spectrum of symptoms of MHS-related myopathy encompasses muscle cramps, stiffness, myalgias, rhabdomyolysis, and weakness, with a wide age range of onset mainly during adulthood. Histopathological analysis can reveal nonspecific abnormalities suggestive of RYR1 involvement, while metabolic profiling reflects altered energy metabolism in MHS muscle. Myopathic manifestations can significantly impact patient quality of life and lead to functional limitations and socio-economic burden. While currently available therapies can provide symptomatic relief, there is a need for further research into targeted treatments addressing the underlying pathophysiology. Counselling early after establishing the MHS diagnosis, followed by multidisciplinary management involving various medical specialties, is crucial to optimise patient care.en
dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0007091224004197
dc.identifier.doi10.1016/j.bja.2024.05.046
dc.identifier.urihttps://hdl.handle.net/11600/71546
dc.identifier.uri10.1016/j.bja.2024.05.046
dc.languageeng
dc.publisherBritish Journal of Anaesthesia
dc.relation.ispartofBritish Journal of Anaesthesia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGenetic testingen
dc.subjectMalignant hyperthermia susceptibilityen
dc.subjectMuscle crampsen
dc.subjectMyopathyen
dc.subjectRhabdomyolysisen
dc.subjectRYR1en
dc.titleMyopathic manifestations across the adult lifespan of patients with malignant hyperthermia susceptibility: a narrative reviewen
dc.typeinfo:eu-repo/semantics/article
unifesp.campusEscola Paulista de Medicina (EPM)
unifesp.departamentoCirurgia
unifesp.graduacaoMedicina
unifesp.graduateProgramNeurologia-Neurociências
unifesp.knowledgeAreaNeurologia
unifesp.researchAreaHipertermia maligna
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
BJA-2024- Myopathy review.pdf
Tamanho:
1.04 MB
Formato:
Adobe Portable Document Format
Descrição:
Licença do Pacote
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
5.55 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Coleções